Kerecis develops the  the Kerecis™ Omega3 acellular dermal matrix technology for use in products to treat chronic wounds, for dura mater repair, breast reconstruction and abdominal wall reconstruction. Our patent pending acellular fish skin derived material improves upon current human and porcine technologies through improved economics and clinical performance, reduced disease transfer risk and absence of cultural constraints on usage.

Kerecis develops the mOmega3™ fatty acid technology for use in several dermatological indications, including; psoriasis, eczema, dermatitis, keratosis pilaris and pseudofolliculitis.



Facilitate healing through tissue regeneration. 



Our vision at Kerecis is to become a world leader in tissue regeneration by providing products that help chronic wounds and damaged tissue to heal. Kerecis will do so by developing innovative technologies based on fish tissue and the components thereof.


Company History

Kerecis was established as a medical device / biotech company in 2009 and completed its seed round early 2010. In 2011 the company closed its "A1" round, late 2012 round “A2” was closed and round "A3" was closed at the end of 2013.

The company is targeting the close of its "B" round in the fall of 2015.

The company is actively seeking future licensing and distribution partners, while focusing on product development, intellectual property protection and clinical tests. Ideal potential technology licensees will have the ability to undertake market launch of these proprietary devices in markets around the world.